[1]张鹏 刘金波 王宏宇.不同生物标志物在静脉血栓栓塞症中应用价值的研究进展[J].心血管病学进展,2021,(11):978-981.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
　ZHANG Peng,LIU Jinbo,WANG Hongyu.Application Value of Different Biomarkers in Venous Thromboembolism[J].Advances in Cardiovascular Diseases,2021,(11):978-981.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
点击复制

不同生物标志物在静脉血栓栓塞症中应用价值的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年11期
页码:
978-981
栏目:
综述
出版日期:
2021-11-25

文章信息/Info

Title:
Application Value of Different Biomarkers in Venous Thromboembolism
文章编号:
202105020
作者:
张鹏1 刘金波 1; 2 王宏宇 1; 2; 3
(1.北京大学首钢医院血管医学中心,北京 100144;2.北京大学医学部血管健康研究中心,北京 100144;3.北京大学分子心血管学教育部重点实验室,北京 100144)
Author(s):
ZHANG Peng1; LIU Jinbo1; 2; WANG Hongyu1; 2; 3
(1.Department of Vascular Medicine,Peking University Shougang Hospital,Beijing 100144,China; 2.Vascular Health Research Center of Peking University Health Science Center,Beijing 100144, China; 3.Key Laboratory of Molecular Cardiovascular Sciences(Peking University),Ministry of Education,Beijing 100144, China)
关键词:
生物标志物; 静脉血栓栓塞症; 应用价值
Keywords:
Biomarkers; Venous thromboembolism; Application value
DOI:
10.16806/j.cnki.issn.1004-3934.2021.11.000
摘要:
肺血栓栓塞症和下肢深静脉血栓形成统称为静脉血栓栓塞症，在全世界范围内二者的发病率很高，肺血栓栓塞症亦是一种病死率很高的疾病。目前在指导临床应用中生物标志物的作用越来越受到重视，如何合理选用生物标志物并正确分析其临床应用价值的侧重点，尚缺乏系统性的认识。现对不同生物标志物在静脉血栓栓塞症中的应用价值做一综述。
Abstract:
Pulmonary thromboembolism and deep vein thrombosis of the lower extremities are collectively referred to as venous thromboembolism,both have a high incidence worldwide,and pulmonary thromboembolism is also a disease with a high mortality rate. At present,more and more attention is paid to the role of biomarkers in guiding clinical applications. There is still a lack of systematic understanding of how to rationally select biomarkers and correctly analyze their clinical application value. The application value of different biomarkers in venous thromboembolism is reviewed in this paper

参考文献/References:

[1]中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2019概要[J]. 中国循环杂志,2020,35(9):833-854.

[2]Konstantinides SV,Meyer G,Becattini C,et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society(ERS)[J]. Eur Heart J,2020,41(4):543-603.

[3]Heit JA,Spencer FA,White RH. The epidemiology of venous thromboembolism[J]. J Thromb Thrombolysis,2016,41(1):3-14.

[4]中华医学会外科学分会血管外科学组. 深静脉血栓形成的诊断和治疗指南（第三版）[J]. 中国血管外科杂志（电子版）,2017,9(4):250-257.

[5]中华医学会呼吸病学分会肺栓塞与肺血管病学组,中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会,全国肺栓塞与肺血管病防治协作组. 肺血栓栓塞症诊治与预防指南[J]. 中华医学杂志,2018,98(14):1060-1087.

[6]Weitz JI,Fredenburgh JC,Eikelboom JW. A test in context:D-dimer[J]. J Am Coll Cardiol,2017,70(19):2411-2420.

[7]Nobes J,Messow CM,Khan M,et al． Age-adjusted D-dimer excludes pulmonary embolism and reduces unnecessary radiation exposure in older adults:retrospective study[J]. Postgrad Med J,2017，93(1101):420-424．

[8]Wells PS,Ihaddadene R,Reilly A,et al. Diagnosis of venous thromboembolism:20 years of progress[J]. Ann Intern Med,2018,168(2):131-140.

[9]Stevens H,Peter K,Tran H,et al. Predicting the risk of recurrent venous thromboembolism:current challenges and future opportunities[J]. J Clin Med,2020,9(5):1582.

[10]王峰,张伟华,刘占祥. BNP、TNI水平变化与肺栓塞相关性分析[J]． 国际呼吸杂志,2018,38(1):53-55.

[11]Vuilleumier N,Limacher A,Méan M,et al． Cardiac biomarkers and clinical scores for risk stratification in elderly patients with non-high-risk pulmonary embolism[J]． J Intern Med，2015,277(6):707-716.

[12]Mahajan A,Wun T. Biomarkers of cancer-associated thromboembolism[J]. Cancer Treat Res,2019,179:69-85.

[13]Puurunen MK,Enserro D,Xanthakis V,et al. Biomarkers for the prediction of venous thromboembolism in the community[J]. Thromb Res,2016,145:34-39.

[14]Kilinc G,Dogan OT,Berk S,et al． Significance of serum cardiac troponin I levels in pulmonary embolism[J]． J Thorac Dis,2012,4(6):588-593.

[15]Howard L . Acute pulmonary embolism[J]. Clin Med(Lond),2019,19(3):243-247.

[16]Bhat TM,Atari ME,Garcia LA. Neutrophil lymphocyte ratio in peripheral vascular disease：a review[J]. Expert Rev Cardiovasc Ther,2016,14(7):871-875.

[17]Galliazzo S,Nigro O,Bertù L,et al. Prognostic role of neutrophils to lymphocytes ratio in patients with acute pulmonary embolism:a systematic review and meta-analysis of the literature[J]. Intern Emerg Med,2018,13(4):603-608.

[18]Ozsu S,Abul Y,Gunaydin S,et al. Prognostic value of red cell distribution width in patients with pulmonary embolism[J]. Clin Appl Thromb Hemost,2014,20(4):365-370.

[19]Celik A,Ozcan IT,Gündes A,et al. Usefulness of admission hematologic parameters as diagnostic tools in acute pulmonary embolism[J]. Kaohsiung J Med Sci,2015,31(3):145-149.

[20]Samuelson Bannow BT,Konkle BA. Laboratory biomarkers for venous thromboembolism risk in patients with hematologic malignancies:a review[J]. Thromb Res,2018,163:138-145.

[21]Morelli VM,Br?kkan SK,Hansen JB. Role of microRNAs in venous thromboembolism[J]. Int J Mol Sci,2020,21(7):2602.

[22]Timp JF,Lijfering WM,Flinterman LE,et al. Predictive value of factor Ⅷ levels for recurrent venous thrombosis:results from the MEGA follow-up study [J]. J Thromb Haemost ,2015,13(10):1823-1832.

[23]Ramacciotti E,Blackburn S,Hawley AE,et al. Evaluation of soluble P-selectin as a marker for the diagnosis of deep venous thrombosis[J]. Clin Appl Thromb Hemost,2011,17(4):425-431.

[24]Riva N,Vella K,Hickey K,et al. Biomarkers for the diagnosis of venous thromboembolism:D-dimer,thrombin generation,procoagulant phospholipid and soluble?P-selectin[J]. J Clin Pathol,2018,71(11):1015-1022.

相似文献/References:

[1]郭君君,郑宏超,曹阳.生物标志物对急性心肌梗死介入治疗预后的预测意义[J].心血管病学进展,2016,(1):37.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.010]
　GUO Junjun,ZHENG Hongchao,CAO Yang.Prognostic Significance of Biomarkers in Predicting Acute Myocardial Infarction after Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2016,(11):37.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.010]
[2]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
　YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(11):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[3]耿春晖 关秀茹.MicroRNA作为动脉粥样硬化的诊断生物标志物的研究进展[J].心血管病学进展,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
　GENG Chunhui,GUAN Xiuru.microRNA as a Diagnostic Biomarker for Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(11):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
[4]晏露 李欣 柳志红.不同生物标志物在急性肺血栓栓塞症中的应用价值[J].心血管病学进展,2019,(5):687.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.007]
　YAN Lu,LI Xin,LIU Zhihong.The unction of Different Biomarkers in Acute Pulmonary Embolism[J].Advances in Cardiovascular Diseases,2019,(11):687.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.007]
[5]刘壮壮 黄宇理.心力衰竭生物标志物的研究进展[J].心血管病学进展,2020,(1):67.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.018]
　LIU Zhuangzhuang,HUANG Yuli.Biomarkers for Heart Failure[J].Advances in Cardiovascular Diseases,2020,(11):67.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.018]
[6]王同霞 陈章荣.可溶ST2与心力衰竭患者预后的评价[J].心血管病学进展,2020,(5):495.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.013]
　WANG Tongxia,CHEN Zhangrong.Prognosis of Heart Failure Patients and Soluble ST2[J].Advances in Cardiovascular Diseases,2020,(11):495.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.013]
[7]冯小梅 李彦红.Ⅰ型前胶原羧基端肽和Ⅲ型前胶原氨基端肽在心肌纤维化的研究进展[J].心血管病学进展,2020,(5):517.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.018]
　FENG Xiaomei,LI Yanhong.PCP and PNP in Myocardial Fibrosis[J].Advances in Cardiovascular Diseases,2020,(11):517.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.018]
[8]李谧 李琳.生长分化因子-15在心房颤动中的研究及应用进展[J].心血管病学进展,2020,(7):749.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.0 19]
　LI Mi,LI Lin.Research and Application of Growth Differentiation Factor-15 in Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(11):749.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.0 19]
[9]于博文 修成奎 王雪 杨静 雷燕.内皮微粒在临床中的研究进展及应用[J].心血管病学进展,2021,(1):76.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
　YU Bowen,XIU Chengkui,WANG Xue,et al.Research Progress and Application of Endothelial Microparticles in Clinic[J].Advances in Cardiovascular Diseases,2021,(11):76.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
[10]刘月娥 关秀茹.循环miRNA作为冠心病潜在生物标志物的研究进展[J].心血管病学进展,2021,(2):171.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.019]
　LIU Yuee,GUAN Xiuru.Research Progress of Circulating Mirna as a Potential Biomarker of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2021,(11):171.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.019]

更新日期/Last Update: 2021-12-06